SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.8% to RMB 7.72 billion.

Innovation remained the engine of Hengrui's growth: Innovative drug sales increased by 26.1% year-on-year to RMB 16.34 billion, contributing 58.3% to total drug sales. This was driven by a robust pipeline across therapeutic areas, with oncology products contributing RMB 13.24 billion in revenue (+18.5% YoY), and non-oncology products contributing RMB 3.10 billion in revenue (+73.4% YoY).

Hengrui kept innovation at its core, with R&D expenditure reaching RMB 8.72 billion in 2025, accounting for 27.6% of total revenue, of which RMB 6.96 billion was expensed. During the year, the company secured seven approvals for ...